Arecor Therapeutics plc (LON:AREC – Get Free Report)’s stock price rose 6.1% on Thursday . The stock traded as high as GBX 70 and last traded at GBX 70. 12,959 shares changed hands during trading, a decline of 45% from the average session volume of 23,612 shares. The stock had previously closed at GBX 66.
Arecor Therapeutics Price Performance
The company has a 50 day moving average price of GBX 62.84 and a 200-day moving average price of GBX 66.55. The company has a quick ratio of 6.24, a current ratio of 4.35 and a debt-to-equity ratio of 1.52. The company has a market cap of £26.43 million, a price-to-earnings ratio of 35.00 and a beta of -0.18.
Arecor Therapeutics Company Profile
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
